<DOC>
	<DOC>NCT01090622</DOC>
	<brief_summary>The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).</brief_summary>
	<brief_title>Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)</brief_title>
	<detailed_description />
	<mesh_term>Erythromelalgia</mesh_term>
	<criteria>The study requires you to: Be1875 years old Have inherited erythromelalgia Be experiencing pain caused by erythromelalgia (Moderate pain score 4/10) Be generally healthy (apart from your pain) Stop taking your usual pain medications for 9 days Not be pregnant or breastfeeding Your role in the study includes: An outpatient screening visit 9days/8 nightsinpatient treatment visit at Nijmegen Medical Center (where you will be closely monitored) A follow up phone call (after your return home) Taking the investigational medication daily Recording your pain levels daily during stay at the Medical Center. Coexistent source of pain from other conditions Receiving professional psychological support for dealing with IEM Treatment for significant depression within 6 months of screening Active HIV, Hepatitis B or C Use of prescription or OTC medication between checkin and discharge Women who are pregnant, or lactating Not currently using adequate contraception Alcoholism or alcohol or substance abuse Presence or history of major psychiatric disturbance Unwilling or unable to comply with all dietary and activity restrictions Any other condition or finding that may pose undue risk for participation Use of any other investigational drug in the 60 days prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>